Cantor Fitzgerald Analysts Lower Earnings Estimates for FATE

Key Points

• Cantor Fitzgerald has decreased its FY2026 earnings estimate for Fate Therapeutics from ($0.73) to ($0.93) per share, reflecting a bearish outlook for the biopharmaceutical company's financial performance.
• Fate Therapeutics' stock price recently opened at $1.11, with a 12-month low of $0.6611 and a high of $4.20, indicating significant volatility within the year.
• The consensus rating for Fate Therapeutics among analysts is a "Hold," with a target price set at $3.30, as several analysts have issued mixed ratings on the stock.

Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2026 EPS estimates for shares of Fate Therapeutics in a research report issued to clients and investors on Wednesday, August 20th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earnings of ($0.93) per share for the year, down from their previous estimate of ($0.73). The consensus estimate for Fate Therapeutics' current full-year earnings is ($1.63) per share.

Several other analysts also recently weighed in on FATE. Robert W. Baird dropped their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 14th. Wells Fargo & Company dropped their price objective on shares of Fate Therapeutics from $4.00 to $2.50 and set an "equal weight" rating on the stock in a report on Wednesday, August 13th. Barclays dropped their price objective on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, August 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a report on Thursday, June 12th. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Fate Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $3.30.

Fate Therapeutics Price Performance

NASDAQ:FATE traded up $0.02 during trading hours on Friday, hitting $1.13. 513,683 shares of the company were exchanged, compared to its average volume of 2,024,156. The stock has a market capitalization of $129.75 million, a price-to-earnings ratio of -0.78 and a beta of 2.24. Fate Therapeutics has a 52-week low of $0.66 and a 52-week high of $4.20. The company's 50 day moving average price is $1.13 and its 200-day moving average price is $1.13.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.06. The firm had revenue of $1.91 million during the quarter, compared to analyst estimates of $1.16 million. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%.

Institutional Investors Weigh In On Fate Therapeutics

A number of hedge funds have recently modified their holdings of FATE. Tang Capital Management LLC raised its position in shares of Fate Therapeutics by 165.1% in the fourth quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company's stock valued at $3,062,000 after buying an additional 1,155,954 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Fate Therapeutics by 67.8% in the first quarter. Acadian Asset Management LLC now owns 2,473,565 shares of the biopharmaceutical company's stock valued at $1,952,000 after buying an additional 999,773 shares during the last quarter. Monaco Asset Management SAM grew its holdings in shares of Fate Therapeutics by 250.9% in the first quarter. Monaco Asset Management SAM now owns 1,149,708 shares of the biopharmaceutical company's stock valued at $908,000 after purchasing an additional 822,037 shares during the period. Vestal Point Capital LP grew its holdings in shares of Fate Therapeutics by 46.3% in the fourth quarter. Vestal Point Capital LP now owns 2,465,000 shares of the biopharmaceutical company's stock valued at $4,067,000 after purchasing an additional 780,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Fate Therapeutics by 38.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 2,203,323 shares of the biopharmaceutical company's stock valued at $1,741,000 after purchasing an additional 616,336 shares during the period. 97.54% of the stock is currently owned by institutional investors and hedge funds.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.